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Abstract
The primary goal of this work was to establish a model system wherein a controlled level
of damage is induced to a sample of normal cartilage, such that damage and repair can be
observed by the dGEMRIC method of MR imaging. Primarily this included the iterative design
of a cartilage tissue holder and testing of its ability to approximate uniaxial diffusion, as well as
observation of glycosaminoglycan degradation induced by ADAMTS using dGEMRIC and
DMMB assays.
The mean uniaxial degradation rate for 20nM ADAMTS was 0.17 mm/day ± 0.08 (1 , n
= 4). The shape of the diffusion front was mostly flat, with attributable factors such as vascular
structures affecting the shape. These consistencies made ADAMTS an acceptable choice for a
degradation agent in the model system.
A final holder design was created that proved largely successful in limiting access of
ADAMTS to a single surface, as demonstrated by the flat diffusion/degradation front. This led to
a good approximation of uni-axial diffusion and fit well with simple mathematical models of
diffusion and previously determined diffusivities of Gadolinium agents in cartilage. A model
system using ADAMTS as a degradation agent and dGEMRIC methods of observation can now
be implemented for exploration of cartilage's ability to repair itself.
Thesis Supervisor: Martha Gray
Title: Edward Hood Taplin Professor of Medical & Electrical Engineering
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Chapter 1. Introduction
Arthritis is a common affliction that lowers the quality of living for millions of people.
Despite the prevalence of this condition, there is a fundamental lack of understanding of arthritis.
A primary reason for this is an absence of knowledge of the pathophysiological processes of
cartilage. In particular how chondrocytes, the cells of cartilage, initiate and carry out repair
functions to the extracellular matrix.
One method of investigating cartilage repair is the use of enzymes to induce specific
damage to regions or molecules of the cartilage matrix. The ability of the cartilage to then repair
the induced damage can be monitored. This may include both the rate and the degree of
recovery, as well as spatial variations of recovery in regions of the cartilage. In addition, studies
could explore whether a 'point of no return' exists for induced damages, and how recovery
capacity changes as this induced damage level is approached.
A problem of exploring the inner functions of tissues, in this case cartilage, is the
necessity for non-destructive and non-invasive means of examination. Magnetic Resonance
Imaging (MRI) provides an excellent means of imaging without physically altering or destroying
a sample. Of particular interest here is the dGEMRIC method, a form of microMR imaging that
has been developed to study cartilage. Delayed Gadolinium (Gd) Enhanced Magnetic Resonance
Imaging of Cartilage (dGEMRIC) uses Gd as a "probe" of the inner function of cartilage. For
example, to map the glycosaminoglycan (GAG) content of cartilage, a negatively charged Gd
agent can be used. In the case of the dGEMRIC method, the negatively charged gadolinium
agent Gd(DTPA)2- saturates a cartilage sample with an inverse distribution to negatively charged
GAG. This allows for a determination of GAG distribution using dGEMRIC. The use of
dGEMRIC over time would allow for the determination of changes in GAG. GAG chains make
up most of the large protoeglycan macromolecules that are part of the cartilage extracellular
matrix, and are important for the proper load-bearing function of cartilage. They are lost during
disease, and this loss is partially responsible for the loss of functional integrity of cartilage. For
this reason, dGEMRIC measurements of GAG concentration may serve as a surrogate measure
for the internal function of cartilage.
As noted earlier, one way to gain insight into cartilage repair mechanisms is to examine
the recovery of cartilage following enzymatic removal of specific macromolecules. dGEMRIC
offers the possibility of visualizing the process during both the degradation and repair phases.
The overall objective of this work is to take advantage of dGEMRIC to establish a model system
wherein a controlled level of damage is induced to a sample of normal cartilage, such that
damage and repair can be observed by dGEMRIC. Accordingly there are two key goals:
Design and testing of a tissue holder (Chapter 2)
Establishing the protocol for inducing damage using a representative GAG-cleaving
enzyme (Chapter 3)
Chapter 2. Tissue holder design and performance
2.1 Design
Design parameters were set down to provide for a uniaxial diffusion model system. This
was achieved primarily by limiting contact of bathing solution to only a single surface of the
tissue sample. The other parameters were primarily logistical, and the full list is as follows:
* Diffusion of bathing solution restricted to a single surface
* Organ culture compatible
* MR compatible
* OD less than 9mm (size limitation for highest image quality)
* Fiducial markers to allow for alignment of different scans
* Structurally sound for reuse (autoclaveable, multiple cycles)
* Cost/ease of construction (reliable manufacture of units in timely manner)
As described below, a series of three holders were constructed, making iterative improvements in
addressing the design parameters with each new holder.
2.2 Iterative Chamber construction
Holder A was designed for a cartilage disk of 6mm in diameter and 3mm in thickness.
The OD of the first holder was 1 mm exactly, too large to fit into the 9mm ID NMR tube that
would need to be placed within the MR coil. Holder A consisted of three pieces: a washer, a
disk, and a cylindrical segment, bonded together with 5-minute epoxy. The third segment had a
small hole in it that was filled with mM Gd in an agar solution. The Gd-active off-center
segment allowed for an axial imaging slice to be taken through it, thereby allowing for
consecutive coronal scans to be aligned for orientation purposes. The schematic for Holder A is
shown in Figure 1. All units are in mm.
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Holder B was designed with a small enough OD to fit inside the 9mm ID NMR tube, so a
10 Omm ID coil can be used, the most sensitive coil likely to be used for future MR studies. This
was accomplished by using a 5mm cartilage disk diameter (reduced from 6mm). To accomplish
this, a number 7 drill was used to create the washer segment (5.1mm ID), slightly larger than the
initial OD of the cartilage to allow for the slight swelling that is normally observed upon
equilibration in solution. From preliminary images of holder A, we learned that polysulfone (the
material used in all of the holders) was visible in MR images, and could be distinguished from
the surrounding solution. Thus, we eliminated the agar-gel-filled fiducial mark, and instead put a
groove on the outer perimeter running the vertical length of the holder. In comparison with
Holder A, Holder B had the same basic operating principles, but had reduced the number of
pieces from 3 to 2, and eliminated the need for agar-filled markers.
Figure 2
The final evolution involved creating the holder as one entire unit, bypassing the need to
epoxy a washer and disc together. This ensured that no solution could leak between the disk-
washer interface and maliciously interfere with the uniaxial diffusion model. As shown in Figure
4, test data for Holder B revealed that the epoxy seal was not adequate for multiple uses. Holder
C was made from a single piece of polysulfone. The OD of the holder was met by lathing down a
larger cylinder of polysulfone (as before). A #7 drill was used to drill 3mm deep along the axis.
To solve the bevel problem caused by the shape of the drill head, another #7 drill bit was
modified to allow for a 90-degree angle. This allowed holder C to be constructed as a single unit.
Compared with Holder B, Holder C improved on the design by eliminating the epoxy, making it
easier to construct and making it autoclavable. Although not tested, the life cycle of Holder C is
likely the best of the three designs. Holder C is dimensionally identical to holder B and therefore
only an isometric diagram of holder C is shown in Figure 2.
2.3 Performance
Key to the performance of the holders is their ability to restrict penetration to the exposed
cartilage surface. All the designs achieved this, in principle, by press-fitting the cartilage into a
well, so that the only way for solutes to enter the cartilage would be through the exposed surface.
Design Schematic for Holder B Isometric Dwg, Holder C
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Leaks in the holder, or a loose fit would be expected to degrade the performance. The design
strategy was assessed by using MR to monitor the uptake of the uncharged Gadolinium agent
Gd(HPDO3A) into the cartilage. An uncharged agent should distribute uniformly throughout the
tissue, unlike ionic Gd(DTPA)2-.
2.3.1 Methods for Performance Testing
The experimental design is that of a simple diffusion experiment. A small plug of
previously frozen bovine nasal cartilage (BNC) was thawed, and a 5mm punch used to create an
z5mm diameter cylinder of cartilage. This was placed inside of the holder (type B), and the
cartilage piece was cut flush to the surface of the holder (5mm OD, 3mm deep). The holder
containing the cartilage was put inside an NMR tube, into which 6 ml of Hanks Buffered Saline
Solution (HBSS) was added and allowed to equilibrate overnight. After obtaining a baseline
image set, the HBSS solution was removed and replaced with 6ml of lmM Gd(HPDO3A)
(Prohance) in HBSS. Images were then obtained repeatedly through the next 24 hours.
All images were obtained using an 8.45 Tesla magnet and a 10 mm ID imaging coil. To
measure T , an "msme_vtr" sequence was used, with 10 relaxation times (100-5000ms)'. Total
imaging time to collect the data for a single T1 map was about 30 minutes. The image plane was
a coronal slice through the shared axis of the cartilage disk and holder. During the uptake
period, 48 consecutive T1 weighted sequences were taken over a period of roughly 24 hours. The
sample remained in the magnet throughout the 24 hours uptake period. Every effort was made to
ensure that the image plane for the uptake images was the same as for the initial baseline image
An in-house image analysis package was used to compute the 49 T1 maps. Briefly, using
Matlab 5.3 and the MRI_Mapper program, the data from each set of 10 TRs were fit to a single
exponential to compute T1 for each image pixel, and create a T1 map. These maps were
computed only for the pixels that were within cartilage (as selected by the user). The resultant
T1 maps for cartilage were presented using color scale, overlaid on the image of the entire
sample (NMR tube, holder and cartilage). The penetration of Prohance is reflected by the
"penetration" of a lower value for T1.
2.3.2 Performance results and discussion
The Prohance uptake study was done twice (Figure 3,4). In both cases the most obvious
trend is that T1 increases progressively from the exposed surface towards the bottom of the
holder, generally confirming that the chambers functioned as designed. This is because Prohance
lowers T1 values, and so higher T1 values at greater depth corresponds to lower penetration of
Prohance. (Because of trouble with the scanning software, the baseline image and the first two
hours of imaging were lost in the first study, but the trend is nevertheless clear.)
By measuring the T1 values in the bottom-most tissue an estimate of the penetration time
was made. For these studies, the time is about 16 hours for 95+% penetration. (Figure 3).
Appendix B, Prohance imaging
Figure 3 Prohance Runs; TI vs. Depth
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This finding has reasonable correspondence with what would be expected by diffusion, as
seen by comparison of the data to theoretical predictions2. Assuming a diffusivity of 3E-6 cm^2/s
for cartilage, the Prohance diffusion observations are within the range of an idealized diffusion
model and values obtained from other researchers (Appendix A).
2 Diffusion model comparison is provided in Appendix A
7
- t 2
t 4
t 8,
t" 12
. -- t 16
: - t 20
)0
2 .
4
8
12
16
20
2500 3000
... 
....
+ t -
t
t -
t %;.
. t -
. t 0.
Figure 4 T gradient created by Prohance diffusion
Prohance Run #1 (t - 2 hrs) Prohance Run #2 (t 2 hrs)
The repeated experiment also served as an assessment of the holder's ability to perform
for multiple cycles. Although primarily effective in limiting diffusion, it is apparent from Figures
3 & 5 that the second experiment's bathing solution gains access to the sides and in particular the
deepest (2.7mm in the case of Prohance Run #2) circumference ring of the disk, implying a poor
washer-to-disk seal. The low T1 values at full depth (circled in pink in Figure 5 and seen in the
contrast of the two graphs in Figure 3) of the Prohance Run #2 is unusual even if there was
leaking between the washer-disk interface, since it can be assumed that even if a leak exists the
top surface of the cartilage is still more exposed to the solution than areas near leaks. When the
experiment was complete, the washer was removed from the disk by hand suggesting the original
epoxy bond had long since lost any structural significance.
Figure 5 Holder Ability To Limit Diffusion
Prohance Run #1 (t - 11 hours) Prohance Run #2 (t 11 hours)
A possible explanation for the low T1 values in the bottom corners of the Prohance Run
#2 (as seen in Figure 5) is the effect of partial-voluming. The coronal slice taken through the
sample has a finite thickness. It is possible that for part of that thickness the scan is picking up
something else, such as air, and thus averaging the T1 of the obstruction into the value. It also
may be that air trapped in the bottom interferes with proper imaging of adjacent areas. If that
were the case there may only be a small air pocket trapped beneath the cartilage sample in
Prohance Run #2, but it may be responsible for the interference seen as a large black mass
occluding the bottom center of the sample.
Figure 6 Prohance Run #2 t .1 hr
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rBoth partial-voluming and air interference on
adjacent areas may lead to this lowered T1
effect. However, it seems unlikely that either
of these is the sole cause. Both of these effects
would lead to this phenomenon occurring for
all time points, not just later ones. Yet for
Prohance Run #2 this effect is not seen in
earlier time points. In Figure 6 the bottom left
and right corners do not have T1 values lower
than any other part of the cartilage.
2.4 Summary of Holder design and performance
In summary, the fabrication of the holders was refined iteratively, with progressive
improvements in relation to the design goals (see Table 1).
Penetration of a contrast agent, assessed for Holder B using MR imaging, indicates that
the primary site of penetration is the exposed cartilage surface, and the penetration rates are
consistent with uniaxial diffusion of the contrast agent. Holder C was never performance tested,
as it is identical to holder B with the exception of being a seamless unit. Therefore it was
assumed to perform to the same standard as holder B without the possibility of interface leakage.
Table I Holder Comparison by Design Parameter
Criteria Holder: A B C
1 Diffusion of bathing solution restricted to a single surface NT 1 NT
2 Organ culture compatible 2 2 2
3 MR compatible 2 2 2
4 OD less than 9mm (size limitation for highest image quality) 0 2 2
5 Fiducial markers to allow for referencing image slices from 2 2 2
different scans together
6 Structurally sound for reuse (autoclaveable, multiple cycles) 0 0 2
7 Cost/ease of construction (reliable manufacture of units in 0 1 2
timely manner) (preferred)
0 = Failed = Criteria Partially Met 2 = Criteria Met NT = not tested
Chapter 3: ADAMTS-induced cartilage degradation
Introduction
The goal is to establish an idealized model system of controlled degradation in a normal
cartilage sample. A representative enzyme whose degradation effects are easily monitored is
necessary. The proteoglycan-cleaving enzyme ADAMTS was purified by and obtained from
collaborators at Pfizer. To evaluate the utility of ADAMTS in establishing a model system,
experiments were designed to ask three questions:
1. Does enzyme-induced damage occur in a front-like pattern?
2. What are the temporal and spatial dynamics of induced damage?
3. Is the effect reproducible?
Q
Note: bl
To that end, an initial experiment, ADAMTS #1 was run with a single sample to gather
preliminary data, implement the use of a holder design, and as a run through for the imaging
protocols. ADAMTS #2 and ADAMTS #3 involved increasing complexity and sample numbers
as described below.
Methods
ADAMTS #1 (1 sample, Holder A):
3.1 Degradation Rate, Diffusion Front
Day 0 * One normal BNC sample was thawed and punched to a 6mm
diameter plug. A scalpel was used to cut the sample to a 3mm
depth. The sample was then placed in holder type A.
* The sample was then equilibrated in 1 ml of 1 mM Gd(DTPA)2 - and
Hank's Balanced Salt Solution (HBSS), then placed in an NMR
tube.
* A baseline image was taken of the sample. The sample was imaged
using 10 relaxation times (100-2700ms), msmevtr (T1 analysis),
3and saturation recovery3 .
* The sample was kept in an incubator at standard cell culture
conditions4 whenever possible.
Days 1,3,5
Days 3,5,7
Day 7
* Solution was replaced with lml of lmM Gd(DTPA)2 - + 20nM
ADAMTS in solution as received from Pfizer.5
* Sample was imaged. (All imaging parameters the same for
ADAMTS experiments, see Appendix B)
* Using Matlab 5.3 and the MRI_Mapper program, the data from
each set of 10 scans were fit to a single exponential to compute T1
for each image pixel, and create a T1 map. These maps were
computed only for the pixels that were within cartilage (as selected
by the user). The resultant T1 maps for cartilage were presented
using color scale, overlaid on the image of the entire sample (NMR
tube, holder and cartilage).
* Degradation rates were determined from the front created by lower
T1 values as Gd(DTPA)2- concentration increased while GAG was
excised by ADAMTS.
ADAMTS #2 (1 sample, Holder C):
3~~~~~~~~~~~~
3 Appendix B, Gd(DTPA)2- imaging parameters
45% C02 , 37°C, humidified
520 ul of 50mM Gd(DTPA) 2 ' was added to 980 ul of 20nM ADAMTS solution as received from Pfizer
10
Normal BNC disk
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3.1.2 GAG loss determination, Degradation Rate, Diffusion Front
Normal BNC disk
* One normal BNC sample was killed by submerging in liquid nitrogen
inside a cryo-tube for -1 minute, then warming in a 37°C water bath
for 15 minutes. This cycle was repeated 3 times.
* Punched to a 5mm diameter disk, 3mm deep.
* Placed in holder type C.
* Sample was equilibrated in lml of lmM Gd(DTPA)2 - and HBSS,
then placed in an NMR tube.
* The sample was kept in an incubator at standard cell conditions
whenever possible.
* Sample was imaged. (Appendix B)
* Solution was removed and frozen for later DMMB Assay analysis
* Sample placed in lml6 of 10:1 (20nM ADAMTS):(Novex7 solution)
+ lmM Gd(DTPA)2-.
* Sample was imaged.
* Solution was removed and frozen for later DMMB Assay analysis
* Cartilage was removed from holder and frozen at-20°C.
* Using Matlab 5.3 and the MRIMapper program, the data from each
set of 10 scans were fit to a single exponential to compute T1 for each
image pixel, and create a T 1 map. These maps were computed only
for the pixels that were within cartilage (as selected by the user). The
resultant T1 maps for cartilage were presented using color scale,
overlaid on the image of the entire sample (NMR tube, holder and
cartilage). Using standard values for cartilage properties8 , GAG
concentration was determined for each day using the average T1
value for the cartilage sample as determined from the MR images.
Total GAG was computed by multiplying the average GAG
concentration by the volume of the cartilage sample (0.06ml).
Comparing consecutive days allowed for the calculation of a daily
GAG loss (mg).
* The Novex solution contains additional salts not present in the
solutions with HBSS. All samples that did not have the Novex
solution in it had a lower salt concentration, that of normal HBSS.
The FCD measurement used to determine GAG concentration from
T1 data relies upon the salt concentration of the solution. Using data
from ADAMTS #3 and a separate control run, it was determined9 that
the salt concentration of the Novex solution was approximately
240mM. The salt concentration of HBSS is 150mM. *much better
* A biochemical DMMB Assay analysis was performed on all aliquots
from Days 1-6 to determine daily GAG losses.
6Prepared 980 ul of 10:1 (20nM ADAMTS solution):(Novex solution), added 20 ul 50mM Gd(DTPA) 2 -. ADAMTS
Lot # KBHOB203
7 Zymogram Developing Buffer (1 OX) from Invitrogen, used as directed by Pfizer
8 See Appendix C Equation 1C
9 See Appendix C, Novex Salt Concentration
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Day 0
Day 1-5
Day 6
ADAMTS #3 (4 samples, Holder C):
3.1.3 GAG loss determination, Degradation Rate, Diffusion Front
RA*| RC NRA NRC
Day 0 * Four normal BNC sample was killed by submerging in liquid nitrogen
inside a cryo-tube for -1 minute, then warming in a 37°C water bath for
15 minutes. This cycle was repeated 3 times.
* Punched to 5mm diameter disks, 3mm deep.
* Placed in holder type C.
* All samples equilibrated in lml of lmM Gd(DTPA)2 and HBSS, placed
in individual NMR tubes.
* All cells kept in incubator at standard cell culture conditions whenever
possible.
* "R" samples placed on an orbital rocker in incubator.
Day 1 * All samples were imaged. (Appendix B)
Day 2-5 * Samples left in incubator.
Day 6-9 * All samples were imaged.
* Solutions removed and frozen for later DMMB Assay analysis
Day 6-9 -After solution -After solution -After solution -After solution
removal placed in removal removal placed in removal
lml of 10:1 (20nM placed in lml lml of 10:1 (20nM placed in lml
ADAMTS):(Novex) of lmM ADAMTS):(Novex) of lmM
+ mM Gd(DTPA) 2 - Gd(DTPA) 2- + mM Gd(DTPA)2 -- Gd(DTPA) 2 -
and HBSS and HBSS
Days * Same as days 6-9 except 36 hours elapsed between days 9-10.5 and
10.5,12 10.5-12.
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* All samples were imaged.
* Solutions removed and frozen for later DMMB Assay analysis
* Cartilage samples were removed from holder and frozen at -20°C.
* Using Matlab 5.3 and the MRI _Mapper program, the data from each set
of 10 scans were fit to a single exponential to compute T 1 for each
image pixel, and create a T map. These maps were computed only for
the pixels that were within cartilage (as selected by the user). The
resultant T1 maps for cartilage were presented using color scale, overlaid
on the image of the entire sample (NMR tube, holder and cartilage).
Using standard values for cartilage properties, GAG concentration was
determined for each day using the average T1 value for the cartilage
sample as determined from the MR images. Total GAG was computed
by multiplying the average GAG concentration by the volume of the
cartilage sample (0.06ml).Comparing consecutive days allowed for the
calculation of a daily GAG loss (mg).
* The Novex solution contains additional salts not present in the solutions
with HBSS. All samples that did not have the Novex solution in it had a
lower salt concentration, that of normal HBSS. The FCD measurement
used to determine GAG concentration from T1 data relies upon the salt
concentration of the solution. Using data from ADAMTS #3 and a
separate control run, it was determined that the salt concentration of the
Novex solution was approximately 240mM. The salt concentration of
HBSS is 150mM.
* A biochemical DMMB Assay analysis was performed on all aliquots
from Days 6-12 to determine daily GAG losses.
v~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
*(R = Rocker NR = No Rocker A = ADAMTS C = Control (no ADAMTS))
3.1.4 Diffusion Front Analysis & Degradation Rate
As described previously, the MATLAB program MRI_MAPPER will generate color-
coded maps of GAG concentrations for each designated time for all samples. These maps will be
used to analyze the shape of the diffusion/degradation front and to calculate degradation rates.
For the front analysis, a later time point image will be taken for each ADAMTS sample. The
front will be visible by the abrupt color change signifying the boundary of ADAMTS'
penetration and degradation of GAG. The image will be qualitatively assessed to see if the shape
of the front is similar to that of later time points (repeatability check). If there is variation within
a sample for similar time points, more than one image will be used for that sample. The shape of
these fronts will be commented on, with regards to the uniformity of degradation depth and front
flatness.
The color GAG concentration maps will be used for all time points on all samples with
ADAMTS to determine a degradation rate'0 . It is suggested from previous data" that pre-
existing vascular structures aids in the diffusion of ADAMTS. With this in mind the degradation
rate measures the shortest vertical distance from the surface of the cartilage to the degradation
edge. For a given sample, this location will be taken in the same location radially for all time
0 Appendix D Calculating Degradation Rate
Michelle Farley, presentation on Model System Developmentfor Cartilage Degradation & Repair
Day 12
points. The measured distance will be divided by the number of days since ADAMTS was first
added, for a degradation rate value in mm/day.
DMMB Assay data was used as another means to assess GAG losses in samples from
ADAMTS #2 and ADAMTS #3. Knowing the GAG losses into solution by the DMMB Assay, it
is possible to determine a corresponding idealized degradation rate. Using the following
assumptions, theoretical degradation rates were derived for the various ADAMTS runs:
* The 3mm deep 5mm diameter cartilage disk has a volume of 0.06ml.
* BNC has a density of 1.1 g/ml.
* 10% of the mass of BNC is GAG, and this was intact for all of the cartilage before
ADAMTS addition.
* Degradation occurred in a front, in uniform depth.
* Degradation was 'all or nothing'. That is degraded cartilage contained 0% GAG, and
cartilage not yet degraded contained 10% GAG.
Results
3.2.1 Degradation Rate
The degradation distances for the ADAMTS experiments are in Table 2. ADAMTS #1
having had no Novex solution added, and ADAMTS #2 & ADAMTS #3 (NRA) containing the
Novex solution (10:1 ADAMTS:Novex) but not placed on a rocker. ADAMTS #3 (RA) also had
(10:1 ADAMTS:Novex solution), and was placed on an orbital rocker while in the incubator. All
'Day' labels refer to the number of days since ADAMTS addition.
Table 2 Degradation Distance From dGEMRIC Images
ADAMTS #1 Degradation Distances (mm)
Day* Total Change Between Measurements
2 0.25 0.25
4 0.50 0.25
6 0.63 0.13
ADAMTS #2 Degradation Distances (mm)
Day* |Total Change Between Measurements
1 0.19 0.19
2 0.25 0.06
3 0.38 0.13
4 0.63 0.25
5 0.81 0.19
ADAMTS #3 Degradation Disances (mm)
Day* |Total Change Between Measurements
RA NRA RA NRA
1 0.38 0.25 0.375 0.25
2 0.50 0.44 0.13 0.19
3 0.75 0.69 0.25 0.25
4.5 1.00 0.88 0.25 0.19
6 1.25 1.00 0.25 0.13
*Days refers to the number of days since the first addition of ADAMTS
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DMMB Assay data was also used to determine a degradation rate, as outlined in 3.1.4. Table 3
shows the GAG losses in mg for ADAMTS #2 and #3, and the projected degradation distances
corresponding to those GAG losses.
Table 3 Degradation Distances From DMMB Assays
DMMB Cumulative GAG losses (mg)
ADAMTS #3 ADAMTS #2
Day |RA RC NRA NRC Day 
1 0.76 0.17 0.65 0.08 1 0.63
2 1.28 0.23 1.17 0.12 2 1.26
3 1.89 0.29 1.73 0.16 3 1.67
4.5 2.38 0.32 2.20 0.21 4 2.18
6 2.94 0.34 2.69 0.23 5 2.72
Degradation Distance - Estimated From DMMB Assay (mm)
ADAMTS #3 ADAMTS #2
Day RA RC NRA NRC Day
1 0.35 0.08 0.30 0.04 1 0.29
2 0.58 0.10 0.53 0.05 2 0.57
3 0.86 0.13 0.79 0.07 3 0.76
4.5 1.08 0.14 1.00 0.09 4 0.99
6 1.34 0.16 1.22 0.11 5 1.24
Degradation Distance - Estimated Change Between Measurements (mm)
ADAMTS #3 ADAMTS #2
Day RA RC NRA NRC Day
1 0.35 0.08 0.30 0.04 1 0.29
2 0.24 0.03 0.24 0.02 2 0.29
3 0.28 0.03 0.25 0.02 3 0.19
4.5 0.22 0.01 0.21 0.02 4 0.23
6 0.25 0.01 0.22 0.01 5 0.25
DMMB Assay data was not collected for ADAMTS #1
Using the distances in Tables 3 & 4,
degradation rates were determined in
mm/day. ADAMTS #1 data was included in
the dGEMRIC data but no DMMB Assay
data was taken for ADAMTS #1. ADAMTS
#1 had the lowest individual degradation
rate, and this no doubt contributed to the
larger standard deviation seen in dGEMRIC
versus the DMMB Assay data.
Table 4 Degradation Rate Comparison
Degradation Rate (mm/day)
Mean 6 Median 
dGEMRIC 0.17 0.08 0.17
DMMB Assay 0.23 0.06 0.24
i's
3.2.2 Diffusion Fronts
Figure 7 has GAG concentration maps for various time points from all four of the
ADAMTS samples from the three experiments. Three of the four samples present fairly uniform
diffusion fronts, with ADAMTS #2 presenting differently.
Figure 7 Degradation Fronts
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from experiment to experiment, since they all had different incubation times in HBSS prior to ADAMTS
addition.
ADAMTS #2 had an obvious vascular
structure in it as seen in the baseline scan in Figure 8.
The sample from ADAMTS #1 had a small break in
the diffusion front on the far right side, as seen in
Figure 7. After the experiment was completed it was
scene that the cartilage sample was torn at this
location, and it is likely the ADAMTS penetration is
due to this. Also, it can be seen that with some of the
ADAMTS experiments there is significant
degradation along the lateral ends of the sample. In
particular in the regions circled with blue in Figure 7.
vascular
structure 
Figure 8
Day 0 ADAMTS #2
(lmM Gd(DTPA)2- in lml HBSS)
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This is likely indicative of the holder's ability to maintain a seal at the surface, and there is
varying success among the samples. (ADAMTS #1 = holder A, all others = holder C) All of the
holders used the same technique for placing the cartilage in the well, and so any variation seen is
due to individual sample variation.
3.2.3 GAG loss determination, dGEfRIC/DMMB analysis
The GAG losses derived from T1 data generated by the dGEMRIC method is plotted
below against DMMB Assay data.
Figure 9 GAG losses (dGEMRIC/TI) vs. DMMB Assay
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For ADAMTS #3 Day 0 was after 5 days of incubation in Iml of ImM Gd(DTPA)- and HBSS
For ADAMTS #2 Day 0 was after overniaht incubation in lml of lmM Gd(DTPA)- and HBSS
In ADAMTS #3 all four samples were left in individual lml solutions of HBSS and
Gd(DTPA) 2- for five consecutive days. In Figure 9 the samples in ADAMTS #3 can be seen
crossing the x-axis above zero. That is to say on Day 0 the samples had already experienced
GAG losses. That is because Day 0 was the day ADAMTS was added, but GAG was lost during
the samples 5-day incubation in HBSS and lmM Magnevist. GAG losses from this were seen
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from ranging from 0.39 - 0.84mg of GAG, with the ADAMTS and control sample on the rocker
being higher with 0.69mg and 0.84mg of GAG loss, respectively. Non-rocker GAG loss values
were 0.53mg and 0.39mg for the ADAMTS and the control experiment, respectively. These
values are the GAG lost in a 5-day period without solution change in lml of HBSS and lmM
Magnevist. This implies that initially GAG is lost to the solution without the assistance of a
degradation enzyme. As seen by the controls in the first two graphs of Figure 9, this leaching
effect dies off quickly and little GAG is lost in subsequent days. ADAMTS #2's aliquot for its
one-day incubation in ml HBSS + lmM Magnevist was not saved, and so no data is available
for it (thus Day 1 is the first GAG loss for ADAMTS #2).
3.3 Discussion
Preliminary data by Michelle Farley had suggested an ADAMTS degradation rate of
0.2mm/day, without using the Novex buffer solution and with no solution changes. ADAMTS #1
(the no-Novex experiment) came in at half of that, at 0.10mm/day. It was anticipated by direction
from Pfizer that the addition of the Novex buffer solution would increase the degradation rate.
Within the three other ADAMTS experiments conducted here it did so from 0.1 0mm/day to
0.16-0.17mm/day for ADAMTS #2 & ADAMTS #3 NRA. ADAMTS #3 RA was slightly higher
than these two, at an average degradation rate of 0.21mm/day, the same as Michelle's initial
experiment without Novex. The majority of samples confirm the preliminary data of a
degradation rate -0.2 mm/day.
Comparing ADAMTS #3's rocker samples versus non-rocker samples before ADAMTS
addition suggests that there is a significant effect on GAG leaching due to the rocker alone.
Before the addition of ADAMTS to these samples, they were all incubated in their own solutions
of lml HBSS + mM Magnevist for 5 days without solution changes. During this time, the two
rocker samples lost an average of 0.3 lmg GAG more than the non-rocker samples, according to
the DMMB Assay. This implies the rocker motion increases initial GAG leaching into solution.
ADAMTS #3 RA was the only ADAMTS solution on a rocker, and it did have the highest
individual degradation rate at 0.21 mm/day. It's not possible with only one ADAMTS sample on
the rocker to determine whether the higher GAG loss is due to enhanced ADAMTS transport, or
due to enhanced GAG leaching into solution. The difference between the ADAMTS #3 RA
sample's degradation rate and the mean was small compared to the standard deviation
(difference of 0.04 mm/day, standard deviation of 0.08 mm/day). Given this and the apparent
increase in GAG leaching due to rocker use as described in the last paragraph, it is likely there is
little increased degradation ability from the rocker's effect of enhancing ADAMTS transport.
The degradation rate as determined by dGEMRIC for the four ADAMTS samples was 0.17
mm/day with a standard deviation of 0.08mm and a median of 0.17mm. This high standard
deviation is partially due to ADAMTS #1, which did not use the Novex buffer, and had an
individual rate of 0.10 mm/day. Because of the absence of Novex buffer, this solution was
expected to have a lower degradation rate. Other variables that were different in the experiments
may have contributed to the large standard deviation. These include using different lengths of
time before solution changes (2 days between changes in ADAMTS #1, and two 1.5 day periods
in ADAMTS #3, vs daily otherwise), and the use of rockers in ADAMTS #3.
The degradation rate as determined by DMMB Assay for the second and third ADAMTS
experiments was 0.23 mm/day with a standard deviation of 0.06mm and a median of 0.24mm.
This number was expected to be higher than the dGEMRIC degradation rates, because of the
assumptions made for the conversion between GAG found in solution (as detected by DMMB
Assays) to a corresponding degraded distance. It is known edges degrade faster due to two
surfaces to diffuse from, the holder-washer seal is not perfect, and that vascular structures aid in
the diffusion and degradation of ADAMTS through a sample. The idealized assumptions made to
determine degradation rates assumed none of these things occurred. Therefore all GAG detected
by DMMB Assay in solution was attributed to uniform degradation in a front, even though some
of it came from other factors. So the calculation over-estimated the amount of GAG due to
uniform degradation, and thus the DMMB Assay determined degradation rate should be higher
than a rate measured directly from the tissue being degraded.from the damaged tissue itself (as
dGEMRIC does).
With the exception of readily detected indicators, degradation occurred in a relatively flat
front, as predicted. The indicators, such as cartilage tears from preparing or vascular structures
can be avoided by careful preparation and detection during baseline scanning, respectively.
Although not perfect, the data suggests that the ability to reliably degrade the GAG content of
the cartilage EC matrix to a uniform depth is feasible.
A limitation of GAG losses determined through the dGEMRIC method is the reliance on
the T1 matrix generated from the MR imaging. As seen in Table 3, interference can obstruct or
partially obstruct the full view of a cartilage sample. This may significantly impact the T1
average for the slice, especially in later stages of degradation where the occluded regions of
cartilage (at the bottom of the sample, where air is trapped in between the holder and the sample)
may have very different T1 values than the degraded upper regions of cartilage. This is primarily
a problem when the obstruction changes in size and shape from day to day, impacting the T 
cartilage averages differently everyday. ADAMTS #3 NRA images had this obstruction problem
most often. This may explain why in Figure 9, the ADAMTS #3 NRA seems to demonstrate a
'wavy' slope of large jumps in degradation and then very small increases. Day to day air
movement would be blocking out different regions of the cartilage sample, this radically
changing day to day GAG losses. If the wavy nature of the slope is due to this, it is likely that the
overall trend is still valid because the summation of variations would cancel eachother out.
The air bubble effect was a twofold problem. By raising the cartilage from the bottom of
the well, it allowed solution to enter and prematurely expose cartilage to the degradation agent.
In addition it lowered the stability of the cartilage in the holder, possibly promoting more
circumferential diffusion of the bathing solution. As noted it presents a problem with GAG loss
determination via imaging, but it is unlikely to have effected degradation depth measurements.
That is because it was apparent that greater penetration occured at the top corners of the
cartilage, due to two surfaces allowing diffusion for ADAMTS. That is why the shortest vertical
distance was used to determine degradation rate as described in 3.1.4 and Appendix D.
Attempts were made to remedy the trapped air problem by placing the cartilage into the
holder while submerged in solution. Alternatively, a syringe needle was placed in between the
cartilage and well wall to evacuate air while the cartilage was being placed into the holder.
Neither of these methods worked completely, but samples fit while submerged appeared to have
the smallest presence of air bubbles (Table 3, ADAMTS #2).
Chapter 4: Thesis summary
The primary goals of this work were to design and test a tissue holder, and to establish a
protocol for inducing damage using a representative GAG-cleaving enzyme. This is to support
the later goal of using dGEMRIC to monitor the repair of the EC matrix of cartilage under
1Q
different states of degradation. The first goal of design and testing of a tissue holder led to an
effective holder after several iterations, and it allowed for a good approximation of a uniaxial
diffusion model in the degradation experiments.
The degradation rates for 20nM ADAMTS was a mean value of 0.17 mm/day ± 0.08 (1
_ n = 4). DMMB Assay GAG losses and a theoretical degradation model yielded slightly higher
results, at 0.23 mm/day + 0.06 (1 _, n = 3). The shape of the diffusion front was mostly flat. This
data suggests that ADAMTS is a good enzyme to induce controlled damage to a specific depth of
a cartilage sample.
Degradation rates and GAG losses that are empirically and rationally consistent with
eachother shows that ADAMTS' use can be largely controlled. Careful sample preparation and
baseline scanning for significant vascular structures can select for samples to best approximate
an ideal diffusion front, allowing for a degradation penetration that is uniform in depth. A robust
protocol can now be established for further testing of the degradation enzyme ADAMTS, or
other advances of the model system.
Appendix A: Diffusion Model
In Figure 7 both Prohance runs are plotted as a percentage of diffusion completion versus
time. Using an idealized diffusion equation as outlined below, a previously derived value for the
diffusivity of Prohance in cartilage was plotted. (D = 1.55E-6 cmA2/sec, seen in pink below)12
Using this diffusion equation a 'best fit' value was qualitatively determined to be 3E-6 cmA2/sec,
which is within the range of the value determined by Gillis et al. The two Prohance runs are seen
in blue.
Figure 10
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12 Relaxivity and Diffusion of Gadolinium Agents in Cartilage, Gillis, Gray, Burstein.
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Diffusion in a semi-infinite medium13 with boundary conditions:
* Interface kept at constant concentration Co
* Initial concentration is zero throughout the depth of the cartilage (medium)
* 0 < x < I is the distance covering the medium ( is the depth of the cartilage, 3mm in this
case)
* Distances I and greater are the infinite solution
* There is no diffusion across the plane x = 0 (bottom of the 3mm cartilage depth)
* Concentration (C) is a function of depth (x)
C-0C * (-1)"erfc (2n +1)l- x * . (n1)2 J(Dt)2 (Dt)C = C0 *;~ ( -1)ec2 + C°*; (-1)"~erfc (2 +i + x
Numerical summation was performed using Microsoft Excel for n = [0-7]. Values at n = 7
converged to near zero for all times, with the largest value less than 1E-6 of a percent of the final
summation.
Appendix B: MRI Parameters
Gd(HPDO3A) (trade name Prohance, from Bracco Diagnostics) Runs:
Used to test design parameters of holder
Bruker 8.45 Tesla Magnet
10mm coil
Saturation Recovery
Sequence - msme_vtr
TE: 15ms
TR (#=10): (100, 150, 300, 400, 600, 900, 1400,2000, 3200, 5000)
Averages: 1
Slice Package = 1 * 0.5mm coronal
Matrix= 128 x 128
FOV= 1.28 cm
Gd(DTPA)2- (trade name Magnevist, from Berlex Imaging) Runs:
Necessary for dGEMRIC imaging of GAG losses due to degradation
Bruker 8.45 Tesla Magnet
10mm coil
Saturation Recovery
Sequence - msme_vtr
TE: 15ms
TR (#=10): (100, 125, 175, 275,375, 475, 600, 900, 1800, 2700)
Averages: 2
Slice Package = 1 * 0.5mm coronal
Matrix = 128 x 128
FOV = 1.28 cm
13 Crank, The Mathematics of Diffusion 2nd Edition, Equation (2.54) (pg 22)
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Appendix C Novex Salt Concentration
A control scan was run to determine the effects of the Novex solution's salt concentration
on the computation for the GAG concentration. The Fixed Charge Density (FCD) is a set
cartilage property that is needed to make the calculation for GAG concentration from T data.
The FCD determination calculation from T1 data is affected by the salt concentration, and the
Novex buffer contains a greater (and unknown) salt concentration than HBSS. Therefore a
baseline scan was taken of a cartilage sample that was prepared in the same manner as used for
all samples in ADAMTS #3. This sample was then equilibrated in lml of HBSS and lmM
Magnevist overnight. The following day the sample was scanned following the Magnevist
parameters used for all ADAMTS experiments. After the scan the solution was replaced with
lml of 10:1 (HBSS):(Novex) and lmM Magnevist. Previously for ADAMTS experiments the
solution for ADAMTS samples were made up of (20nM ADAMTS):(Novex) and lmM
Magnevist. The control was left overnight in its HBSS/Novex/Magnevist solution and scanned
the following day. The resulting images are below.
Figure 11 Novex Control Run
It can be seen that the day after incubating in
the HBSS/Novex/Magnevist solution the
sample has unusually low T1 values, normally
indicative of lowered GAG values. Although
the T1 values are lower, the GAG
concentration is not 14 . Normally, a T1 average
is taken of the whole slice and converted to a
GAG concentration. Equation 1 C below
represents the general format to calculate
GAG concentration. In the baseline scan theI ,. 1_ I - -- -_ r l_ -1_
solution nad a 1 1 value or U. I 1, 1 1 cartilage
average of 0.492, salt concentration of 150mM
(standard for all solutions without Novex) and
a final GAG concentration of 11 Omg/ml. The
post-Novex scan had a solution T1 value of
0.190, T1 cartilage average of 0.362, an
unknown salt concentration, and an assumed
GAG concentration of 1 Omg/ml (unchanged
from the day before). With this data, it was
determined that the Novex solution had a salt
concentration of 240mM.
Equation 1C
[Gd](bath)= /R(bath)*(/BathT1+ - 1/SalineT1)
14 Based on control data from ADAMTS#3, the assumption is made here that no GAG losses occur between Day 0
and Day 1 scans
Day 0: Baseline Scan (1 Day in HBSS +
Magnevist)
Day 1: Novex Addition (1 Day in 10:1 HBSS:
Novex + Magnevist)
.A -
[Gd](cartilage) = 1 /R(cartilage) * (1/T1 Gd - 1/T1 Gd)
FCD = 2 * [salt concentration] * ([Gd]bath- [Gd](cartilage))/([Gd]bath * [Gd](cartilage))
[GAG] =-0.5 * .5025 * FCD
T1 Saline = 2.75; T1 Cartilage (equilibrated in saline) = 1.6;
Relaxivity Cartilage = 4.6; Relaxivity Bath = 4.35
All other T values are measured using MR Imaging
Appendix D Calculating Degradation Distances
The degradation rates for the ADAMTS samples were calculated as follows:
* The image file was imported into Adobe Photoshop.
* A reference line was drawn that runs the entire depth of the holder. This reference line
corresponds with 3mm. All of the holders were manufactured with a well depth of 3mm
(in the case below, the longer of the two lines).
* The reference line was then subdivided into 48 even parts, digitally. Each of these
subdivisions corresponded to a length of 1/16th of a mm.
* Another line was drawn running from the cartilage's top surface down to the edge of the
degradation front (the shorter of the two lines below). The shortest distance was taken,
therefore areas like those circled were avoided. This was done because most jumps in the
degradation front were due to vascular structures and edge effects, not a product of
uniaxial degradation through the EC matrix.
* The line measuring the depth of the degradation front penetration was then compared to
the reference line. A degradation penetration depth was then measured. This was then the
cumulative degradation distance for that sample on that day. The difference of
consecutive days measurements was the daily distance degraded. The measurement error
was 1/16 th of a mm, the smallest subdivision of the reference line.
* This was done for all time points for all ADAMTS samples. The mean value, standard
deviation, and median value were calculated (Table 4).
Figure 12
